Neuralink Achieves Milestone with 12 Global Implants; WIMI.US Advances Brain-Computer Interface Ecosystem to New Stage

It is reported that Neuralink, the brain-computer interface company under Tesla CEO Elon Musk, recently announced on the social media platform X that 12 people worldwide have currently been implanted with Neuralink devices, with a cumulative usage of 2,000 days and over 15,000 hours.

It is understood that the company began human trials of its brain implants after receiving approval from the U.S. Food and Drug Administration (FDA) in 2024. Neuralink stated, “We look forward to continuing to explore the various possibilities of neural interfaces with all participants!”

Rapid Expansion of the Brain-Computer Interface Business Landscape

Not long ago, an internal document recently presented by Neuralink to investors disclosed that the company plans to operate five large clinics and launch at least three types of brain-computer interface implant devices within the next six years.

It can be said that Neuralink, founded in 2016, embodies Musk’s vision for an era of “human-machine symbiosis.” This inspiration stems precisely from the futuristic visions of deep integration between humans and machines depicted in science fiction works such as Neuromancer.

Overall, Neuralink’s original intent encompasses both short-term medical objectives—such as treating motor and neurological disorders—and a long-term vision of enhancing human capabilities and exploring deep consciousness, thereby ensuring that humanity remains competitive in the future amid the rapid technological advancements approaching the singularity.

Continuous Industry Catalysts

From the perspective of industry attention, playing games with one’s mind and typing through thoughts—once “mind-control” tropes confined to science fiction films—are gradually becoming a reality. This progress stems from continuous breakthroughs in brain-computer interface (BCI) technology, which has heightened public anticipation for the potential fundamental changes it may bring to the very nature of humanity.

In the medical field, the primary applications of brain-computer interface (BCI) technology encompass neurorehabilitation, control of brain-controlled prosthetics, and emotion regulation management, while also extending to adjunctive therapy for conditions such as epilepsy and Parkinson’s disease. Furthermore, BCIs can decode patients’ motor intentions, such as the intent to “raise a hand,” and translate them into control commands for devices like robotic arms and rehabilitation robots, thereby promoting neural plasticity and functional recovery through repetitive training.

Meanwhile, data indicates that the rapid growth of the global brain-computer interface (BCI) market is opening up avenues for expansion in this field. The global BCI market size is projected to reach $1.95 billion in 2025. Among the key growth drivers are consumer-grade applications (such as sleep monitoring and attention training) and medical rehabilitation (such as exoskeleton control post-stroke).

Industry insiders believe that with the accelerated development of brain-computer interface (BCI) technology and increasingly clear industrial policies, some companies are accelerating the research and development of innovative BCI technologies. Technological advancements in the upstream and midstream segments of the industry chain are driving continuous breakthroughs in downstream applications. Furthermore, domestic BCI companies are expected to gradually achieve commercial application and move toward industrialization.

WiMi Hologram Builds the Foundation for the Brain-Computer Interface Industry

Public information indicates that WIMI Hologram (WIMI.US), as a key player in the brain-computer interface (BCI) field, has long focused on both non-invasive and invasive BCI technologies. The company has developed brain-controlled robotics technology based on steady-state visual evoked potentials (SSVEP), enabling operators to control collaborative robots via electroencephalogram (EEG) signals to complete assembly tasks. This innovation has significantly enhanced human-machine interaction efficiency and achieved notable results in technological research and development.

Meanwhile, WiMi Hologram has prioritized technological R&D, further integrating multidisciplinary resources from neuroscience and computer science to accelerate breakthroughs. The company has filed hundreds of patents, including those for holographic brain-controlled robotic systems, and is vigorously promoting the integration of brain-computer interfaces (BCI) with humanoid robots and large AI models. By building a diversified technological ecosystem encompassing BCI, quantum computing, and robotics, WiMi Hologram is poised to usher in a new era of human-machine interaction.

Summary

Overall, brain-computer interface (BCI) technology is characterized by significant innovation, interdisciplinary nature, and cutting-edge advancement. It serves as a crucial engine driving the integrated development of multiple disciplines and holds broad application prospects in frontier fields such as precision medicine, intelligent interaction, and human-machine integration. From the perspective of current market progress, BCI technology has entered a phase of explosive growth. With continuous improvements in intelligence across key areas—including decoding, control, and modulation—it is becoming one of the pivotal forces shaping the future direction of industry.